Generation Bio (GBIO) Company Total Revenue

Generation Bio Co. (GBIO) utilizes artificial intelligence to design therapies, although final control remains with physicians. Corporate sales reflect market demand dynamics, while 0.02 records a new level mark. The company's technological moat is built upon a unique DNA delivery system, and the automation of molecular genome screening via robotic stations accelerates the development of innovative drugs.

generationbio.com - GBIO Company Sales (period 07/04/2022 - 02/21/2026)

Comprehensive metric breakdowns and analytics for Generation Bio Co (GBIO)

- market value and analyst target forecast:

Market Chart Generation Bio Corp|GBIO - Price Target Chart

- market capitalization details:

Market Value Generation Bio Co.|GBIO - Total Company Value

- book value of equity indicators:

Equity per Share Generation Bio|GBIO - Company Net Assets|Market Value to Book Value generationbio.com|GBIO - Company Total Assets

- company liabilities and liquidity data:

- financial results and valuation multiples details:

GBIO - Company Net Income|Expected Net Profit Generation Bio Co.|GBIO - Price to Earnings Ratio|Market Cap to Projected Earnings Generation Bio Corp|GBIO - PEG Multiple|Enterprise Value to EBITDA Multiple Generation Bio Co.|GBIO - Operating profit EBITDA|Earnings per share for the last twelve months Generation Bio|GBIO - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months generationbio.com|GBIO - Earnings per share growth in current year|Expected net earnings per share growth next year Generation Bio Co.

- issuer revenue and sales details:

GBIO - Revenue and Sales Volume|Company Revenue Forecast Generation Bio Corp|GBIO - Price-to-Revenue Ratio|Market Cap to Projected Revenue Generation Bio Co.

Comprehensive company analysis:GBIO (generationbio.com)

Investors verify issuer reliability by comparing fundamental multiples with actual cash flows. This sales data set for Generation Bio Co. (GBIO) allows for the tracking of daily revenue, eliminating accounting manipulations and identifying cash gap risks. For Generation Bio Co. (GBIO), the absence of proprietary sales is expected, as research is fully funded by a strategic Big Pharma partner. Consistently low values confirm the current organic development phase without product commercialization.

Competing companies